Applied UV (AUVI) Stock: Why The Price Increased Today

By Amit Chowdhry ● Dec 1, 2021
  • The stock price of Applied UV Inc (NASDAQ: AUVI) increased by over 5% during intraday trading. This is why it happened.

The stock price of Applied UV Inc (NASDAQ: AUVI) – a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (UVC) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically – increased by over 5% during intraday trading. Investors are responding positively to Applied UV announcing that its exclusive distribution partner in Thailand will be installing Airocide units at the Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand, to help create safer and cleaner environments for visitors and staff.

AFRIMS is a biomedical research facility of the U.S. Army’s Walter Reed Army Institute of Research (WRAIR). And AFRIMS- with a mission that has resulted in ground-breaking research in military medicine across nations in Southeast Asia and the Indian subcontinent – has primarily focused on diseases related to infectious pathogens.

AFRIMS has a dual Royal Thai Army and US Army Command with the American Component being a special foreign activity of the WRAIR in Washington, DC. And since 1893, the WRAIR has been a leader in solving significant threats to soldier readiness and lethalities like disease and battle injury. And WRAIR’s broad research capabilities at its Washington, D.C., area and expeditionary laboratories function in concert to afford Soldiers the best medical protection and support possible before, during, and after deployment by addressing both longstanding and emerging threats. Even though WRAIR’s research is focused on Soldier health, its products have important civilian applications, saving countless lives around the world.

With the ongoing battle against COVID-19 and the recent global emergence of the new Omicron strain, AFRIMS is installing Airocide systems to control airborne diseases and protect critical areas within the facility. And the installation of the Airocide GCS series units at the research facility demonstrates the commitment of Thailand’s medical community to seek out and provide the best-in-air purification and sanitizing technology by which to protect their employees.

Armed with one of the only known FDA Listed Class II Medical Devices that has been clinically proven to kill COVID 19, Applied UV continues to enhance its distributor relationships throughout Southeast Asia and around the world to meet the demand for its air and surface infection control products. And the installation at this leading military research facility coupled with other global installations (JetBlue Park, Boston Red Sox, US Army Aberdeen Proving Grounds, Bangkok Metropolitan Administration Lat Krabang Hospital, Palace of Versailles) further demonstrates the efficacy and safety of the patented Airocide air purification platform by having these institutions trust the protection of their staffs, consumers and facilities with our product.

Airocide utilizes NASA optimized photocatalytic oxidation (PCO) technology wherein air and any contaminants are drawn from the room into the Airocide unit and channeled into the reaction chamber. And UVC activates the proprietary photocatalyst embedded in the reaction chamber, beginning the photocatalytic process.

In the reaction chamber, hydroxyl radicals and super-oxide ions are generated and oxidize every organic molecule that comes in contact. And the reaction bed is designed to allow the surface-bound radicals nearly three hundred and sixty degrees of exposure for maximum likelihood of collisions with pathogens and other organic material. Millions of hydroxyl radicals converge – combining with the carbon atoms in pathogens (airborne bacteria, mold, fungi, mycotoxins, viruses, allergens) and VOCs – converting the organic material into a harmless vapor and clean/clear air.


“The installation of our Airocide units at such a prestigious biomedical facility represents another significant milestone in our strategy to significantly grow our international commercial distribution capabilities and enter new markets. Our Thailand distributor, Sithiporn Associates, is one of the leading scientific equipment distributors in Thailand and ASEAN region and have been excellent partners to commercialize our innovative and clinically proven portfolio of pathogen eliminating technology. Hospitals and research facilities are increasingly recognizing the benefits of installing Airocide® systems in communal spaces to interrupt the transmission of airborne infectious agents and destroy those microbes rapidly while keeping the occupants safe from any harmful byproducts.”

— Max Munn, Founder and President of Applied UV

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.